{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:44:07Z","timestamp":1777923847315,"version":"3.51.4"},"reference-count":237,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Nucleic Acid Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from inefficient signaling and insufficient production of insulin. Conventional management of T2D has largely relied on small molecule-based oral hypoglycemic medicines, which do not halt the progression of the disease due to limited efficacy and induce adverse effects as well. To this end, antisense oligonucleotide has attracted immense attention in developing antidiabetic agents because of their ability to downregulate the expression of disease-causing genes at the RNA and protein level. To date, seven antisense agents have been approved by the United States Food and Drug Administration for therapies of a variety of human maladies, including genetic disorders. Herein, we provide a comprehensive review of antisense molecules developed for suppressing the causative genes believed to be responsible for insulin resistance and hyperglycemia toward preventing and treating T2D.<\/jats:p>","DOI":"10.1089\/nat.2020.0891","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T12:58:47Z","timestamp":1602075527000},"page":"39-57","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes"],"prefix":"10.1177","volume":"31","author":[{"given":"Suxiang","family":"Chen","sequence":"first","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia."},{"name":"Perron Institute for Neurological and Translational Science, Perth, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabayet","family":"Sbuh","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia."},{"name":"Perron Institute for Neurological and Translational Science, Perth, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh N.","family":"Veedu","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia."},{"name":"Perron Institute for Neurological and Translational Science, Perth, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1997.0227"},{"key":"e_1_3_4_3_2","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias N","year":"2002","unstructured":"Dias N, and Stein CA. (2002). Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther, 1:347\u2013355.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2006.04403.x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010818-021050"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.10.4370"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.280"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.285"},{"key":"e_1_3_4_9_2","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr B.","year":"1998","unstructured":"Roehr B. (1998). Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care, 4:14\u201316.","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.7.3.189.4007"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0042-2"},{"key":"e_1_3_4_12_2","first-page":"119","article-title":"Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong E","year":"2014","unstructured":"Wong E, and Goldberg T. (2014). Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T, 39:119\u2013122.","journal-title":"P T"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0657-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97635"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpx5204-302"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005680"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0711-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4508"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8651-4_4"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-24.3.194"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285618754459"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14027"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1364159"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018789956"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0968-5"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020078"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2019.29003.aar"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813279"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0286-x"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01267-2"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"e_1_3_4_32_2","first-page":"Jan","article-title":"In: StatPearls [Internet]","author":"Goyal R","year":"2020","unstructured":"Goyal R, , Jialal Diabetes mellitus type 2 I.. (2020). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Jan\u2013. PMID: 30020625.","journal-title":"Treasure Island (FL): StatPearls Publishing; 2020"},{"key":"e_1_3_4_33_2","first-page":"37","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf ME","year":"2013","unstructured":"Cerf ME. (2013). Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne), 4:37.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr5002832"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1052"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986710793361225"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0073"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-48382-5_8"},{"key":"e_1_3_4_39_2","first-page":"1270","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links","volume":"53","author":"DeFronzo RA","year":"2010","unstructured":"DeFronzo RA. (2010). Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia, 53:1270\u20131287.","journal-title":"Diabetologia"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-013-0262-6"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S67400"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.32.s3.3.x"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00372"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2005.07.003"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0123-1"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0410-400"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00396.2009"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.9.2232"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24368"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784139747"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0023"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01279.x"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/515136"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00083"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9912"},{"key":"e_1_3_4_56_2","first-page":"11","volume":"17","author":"Babiker A","year":"2017","unstructured":"Babiker A, and Dubayee MA. (2017). Anti-diabetic medications: how to make a choice? Sudan J Paediatr, 17:11\u201320.","journal-title":"Anti-diabetic medications: how to make a choice? Sudan J Paediatr"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565030-00005"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v7.i17.354"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26001"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0656"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw533"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-003-3045-4"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3625"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000323"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01168-z"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.30"},{"key":"e_1_3_4_67_2","first-page":"1628","article-title":"Antisense technologies","volume":"270","author":"Kurreck J.","year":"2003","unstructured":"Kurreck J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem, 270:1628\u20131644.","journal-title":"Improvement through novel chemical modifications. Eur J Biochem"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1239"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1039\/C4MD00184B"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3765"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.2"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00551"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2014.0506"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst0240630"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104408"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.3.1715"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.200900343"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.4161\/rna.6.3.8807"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.07.001"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201043376706"},{"key":"e_1_3_4_81_2","first-page":"235","article-title":"Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation","volume":"3","author":"Iversen PL","year":"2001","unstructured":"Iversen PL. (2001). Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther, 3:235\u2013238.","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_4_82_2","first-page":"89","article-title":"An introduction to peptide nucleic acid","volume":"1","author":"Nielsen PE","year":"1999","unstructured":"Nielsen PE, and Egholm M. (1999). An introduction to peptide nucleic acid. Curr Issues Mol Biol, 1:89\u2013104.","journal-title":"Curr Issues Mol Biol"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161210793292546"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2012.0366"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.6.2620"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85268-7"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21111582"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42523-0"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.09.002"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1039\/C7RA06091B"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1039\/C6CC07447B"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03850-2"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(00)00062-0"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1089\/ard.1992.2.165"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00286"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn342"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020051"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.02.008"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.06.009"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.04.004"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.61"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw236"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2016.01065"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21479"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0450-0"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.01.008"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat3386"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.17.7595"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)39459-0"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2011.00010"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125228"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.3.591"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0662"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.33.19810"},{"key":"e_1_3_4_115_2","first-page":"4283","article-title":"Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B","volume":"275","author":"Goldstein BJ","year":"2000","unstructured":"Goldstein BJ, , Bittner-Kowalczyk A, , White MF, and Harbeck M. (2000). Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem, 275:4283\u20134289.","journal-title":"Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.142298199"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/6023"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.138"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02839-5"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.21"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.8.2405"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(03)00008-X"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0885"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061321"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.2002-0288"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00490.x"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.12.6336"},{"key":"e_1_3_4_128_2","first-page":"1484","article-title":"Involvement of 3\u2032,5\u2032-cyclic adenosine monophosphate regulatory element binding protein (CREB) in both basal and hormone-mediated expression of the phosphoenolpyruvate carboxykinase (PEPCK) gene","volume":"7","author":"Xing L","year":"1993","unstructured":"Xing L, and Quinn PG. (1993). Involvement of 3\u2032,5\u2032-cyclic adenosine monophosphate regulatory element binding protein (CREB) in both basal and hormone-mediated expression of the phosphoenolpyruvate carboxykinase (PEPCK) gene. Mol Endocrinol, 7:1484\u20131494.","journal-title":"Mol Endocrinol"},{"key":"e_1_3_4_129_2","first-page":"element","article-title":"Inhibition by insulin of protein kinase A-induced transcription of the phosphoenolpyruvate carboxykinase gene","author":"Quinn PG","year":"1994","unstructured":"Quinn PG. (1994). Inhibition by insulin of protein kinase A-induced transcription of the phosphoenolpyruvate carboxykinase gene. Mediation by the activation domain of cAMP eesponse. element-binding protein (CREB) and factors bound to the TATA box. J Biol Chem 269:14375\u201314378.","journal-title":"Mediation by the activation domain of cAMP eesponse"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2006.16.253"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609626200"},{"key":"e_1_3_4_132_2","first-page":"E225","article-title":"Role of glucagon in disposal of an amino acid load","volume":"259","author":"Boden G","year":"1990","unstructured":"Boden G, , Tappy L, , Jadali F, , Hoeldtke RD, , Rezvani I, and Owen OE. (1990). Role of glucagon in disposal of an amino acid load. Am J Physiol, 259:E225\u2013E232.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_133_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.54.030192.004321"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1089999"},{"key":"e_1_3_4_135_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.2.410"},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_3_4_137_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20911"},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.11.011"},{"key":"e_1_3_4_139_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.197426"},{"key":"e_1_3_4_140_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-81265-1_28"},{"key":"e_1_3_4_141_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1984.64.1.170"},{"key":"e_1_3_4_142_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/525093"},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.03.003"},{"key":"e_1_3_4_144_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-81265-1_27"},{"key":"e_1_3_4_145_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1886-0"},{"key":"e_1_3_4_146_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.67.040403.120816"},{"key":"e_1_3_4_147_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2895-8_5"},{"key":"e_1_3_4_148_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1846"},{"key":"e_1_3_4_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.01.030"},{"key":"e_1_3_4_150_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.121164498"},{"key":"e_1_3_4_151_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313478200"},{"key":"e_1_3_4_152_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.3.603"},{"key":"e_1_3_4_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2571(98)00016-8"},{"key":"e_1_3_4_154_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst0301059"},{"key":"e_1_3_4_155_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.52.070183.002541"},{"key":"e_1_3_4_156_2","first-page":"1","article-title":"The mitochondrial carnitine palmitoyltransferase system","volume":"244","author":"McGarry JD","year":"1997","unstructured":"McGarry JD, and Brown NF. (1997). The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem, 244:1\u201314.","journal-title":"From concept to molecular analysis. Eur J Biochem"},{"key":"e_1_3_4_157_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1056843"},{"key":"e_1_3_4_158_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27300"},{"key":"e_1_3_4_159_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20783"},{"key":"e_1_3_4_160_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704213200"},{"key":"e_1_3_4_161_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi060269g"},{"key":"e_1_3_4_162_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R109.040519"},{"key":"e_1_3_4_163_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C113.544759"},{"key":"e_1_3_4_164_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30400"},{"key":"e_1_3_4_165_2","first-page":"phosphohistidin","article-title":"The catalytic center of glucose-6-phosphatase","author":"Ghosh A","year":"2002","unstructured":"Ghosh A, , Shieh JJ, , Pan CJ, , Sun MS, and Chou JY. (2002). The catalytic center of glucose-6-phosphatase. HIS176 is the nucleophile forming the. phosphohistidine-enzyme intermediate during catalysis. J Biol Chem 277:32837\u201332842.","journal-title":"HIS176 is the nucleophile forming the"},{"key":"e_1_3_4_166_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M610759200"},{"key":"e_1_3_4_167_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.66.1.581"},{"key":"e_1_3_4_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2009.10.007"},{"key":"e_1_3_4_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03967"},{"key":"e_1_3_4_170_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601715"},{"key":"e_1_3_4_171_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.460246"},{"key":"e_1_3_4_172_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2013.0456"},{"key":"e_1_3_4_173_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C110.175851"},{"key":"e_1_3_4_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.08.006"},{"key":"e_1_3_4_175_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00156.2003"},{"key":"e_1_3_4_176_2","doi-asserted-by":"publisher","DOI":"10.2337\/db05-0705"},{"key":"e_1_3_4_177_2","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0744"},{"key":"e_1_3_4_178_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5407.1544"},{"key":"e_1_3_4_179_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.3.1639"},{"key":"e_1_3_4_180_2","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-49"},{"key":"e_1_3_4_181_2","first-page":"1392","article-title":"Retinol-binding protein 4 and insulin resistance","volume":"55","author":"Takashima N","year":"2006","unstructured":"Takashima N, , Tomoike H, and Iwai N. (2006). Retinol-binding protein 4 and insulin resistance. N Engl J Med, 55:1392\u20131395.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_182_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.8.3.289"},{"key":"e_1_3_4_183_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.12.031"},{"key":"e_1_3_4_184_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2342"},{"key":"e_1_3_4_185_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.08.016"},{"key":"e_1_3_4_186_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03711"},{"key":"e_1_3_4_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.01.018"},{"key":"e_1_3_4_188_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.06193-11"},{"key":"e_1_3_4_189_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054862"},{"key":"e_1_3_4_190_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0360"},{"key":"e_1_3_4_191_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2034"},{"key":"e_1_3_4_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.09.011"},{"key":"e_1_3_4_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0083-6729(04)69010-8"},{"key":"e_1_3_4_194_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008091200"},{"key":"e_1_3_4_195_2","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0970"},{"key":"e_1_3_4_196_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079817"},{"key":"e_1_3_4_197_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.9.2807"},{"key":"e_1_3_4_198_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700545-JLR200"},{"key":"e_1_3_4_199_2","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/818945"},{"key":"e_1_3_4_200_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1984-5"},{"key":"e_1_3_4_201_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"e_1_3_4_202_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101322"},{"key":"e_1_3_4_203_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.200"},{"key":"e_1_3_4_204_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M504611200"},{"key":"e_1_3_4_205_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2449"},{"key":"e_1_3_4_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.020"},{"key":"e_1_3_4_207_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1166"},{"key":"e_1_3_4_208_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2358"},{"key":"e_1_3_4_209_2","doi-asserted-by":"publisher","DOI":"10.1038\/35021228"},{"key":"e_1_3_4_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(02)01611-8"},{"key":"e_1_3_4_211_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.A109.513304"},{"key":"e_1_3_4_212_2","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-08-0354"},{"key":"e_1_3_4_213_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01137"},{"key":"e_1_3_4_214_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814560735"},{"key":"e_1_3_4_215_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S184437"},{"key":"e_1_3_4_216_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0937-z"},{"key":"e_1_3_4_217_2","first-page":"736","article-title":"Ertugliflozin (steglatro): a new option for SGLT2 inhibition","volume":"43","author":"Kovacich N","year":"2018","unstructured":"Kovacich N, and Chavez B. (2018). Ertugliflozin (steglatro): a new option for SGLT2 inhibition. P T, 43:736\u2013742.","journal-title":"P T"},{"key":"e_1_3_4_218_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01146-5"},{"key":"e_1_3_4_219_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.6.2.153"},{"key":"e_1_3_4_220_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-015-0048-8"},{"key":"e_1_3_4_221_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0686-9"},{"key":"e_1_3_4_222_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0199-3"},{"key":"e_1_3_4_223_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.85934"},{"key":"e_1_3_4_224_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0308-3"},{"key":"e_1_3_4_225_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504076"},{"key":"e_1_3_4_226_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00003"},{"key":"e_1_3_4_227_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2132"},{"key":"e_1_3_4_228_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.396"},{"key":"e_1_3_4_229_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9505-5"},{"key":"e_1_3_4_230_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1343"},{"key":"e_1_3_4_231_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.233809"},{"key":"e_1_3_4_232_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.292"},{"key":"e_1_3_4_233_2","first-page":"698","article-title":"ISIS-GCCRRX, a novel glucocorticoid receptor antisense drug reduces CHOL, TG, attenuates dexamethasone induced hepatic IR without systemic GC antagonism in normal subjects","author":"Morgan E","year":"2013","unstructured":"Morgan E, , Bethune C, , Larouche R, , Xia S, and Geary R. (2013). ISIS-GCCRRX, a novel glucocorticoid receptor antisense drug reduces CHOL, TG, attenuates dexamethasone induced hepatic IR without systemic GC antagonism in normal subjects. EASD Virtual Meeting. Barcelona Session: PS 048 Liver metabolism, Abstract #. 698.","journal-title":"EASD Virtual Meeting. Barcelona Session: PS 048 Liver metabolism, Abstract #"},{"key":"e_1_3_4_234_2","first-page":"121","volume":"33","author":"Chikara G","year":"2018","unstructured":"Chikara G, , Sharma PK, , Dwivedi P, , Charan J, , Ambwani S, and Singh S. (2018). A narrative review of potential future antidiabetic drugs: should we expect more? Indian J Clin Biochem, 33:121\u2013131.","journal-title":"A narrative review of potential future antidiabetic drugs: should we expect more? Indian J Clin Biochem"},{"key":"e_1_3_4_235_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30118-5"},{"key":"e_1_3_4_236_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.300367"},{"key":"e_1_3_4_237_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0126"},{"key":"e_1_3_4_238_2","unstructured":"Akcea Therapeutics. 2020. Study of ISIS 703802 in subjects with hypertriglyceridemia type 2 diabetes mellitus and nonalcoholic fatty liver disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03371355 (accessed April6 2020)."}],"container-title":["Nucleic Acid Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/nat.2020.0891","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2020.0891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2020.0891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:01:50Z","timestamp":1777669310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/nat.2020.0891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":237,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/nat.2020.0891"],"URL":"https:\/\/doi.org\/10.1089\/nat.2020.0891","relation":{},"ISSN":["2159-3337","2159-3345"],"issn-type":[{"value":"2159-3337","type":"print"},{"value":"2159-3345","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}